Testing a new radioactive imaging scan for solid tumors

Plain-English translation of NCT07630961 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This trial is testing a new imaging medication called that uses a small amount of radioactivity to help doctors see cancer cells in the body. Researchers want to understand how this medication works, how safe it is, and whether it can help identify certain types of tumors better than existing imaging methods. The study will also compare this new medication to a similar one already being used.

Many patients with solid tumors need better ways for doctors to locate and monitor their cancer. This medication is being tested because it may help doctors see cancer cells that are harder to spot with standard imaging techniques, potentially leading to better diagnosis and treatment planning.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with advanced pancreatic, lung, breast, colorectal, or soft tissue sarcoma that cannot be surgically removed or has spread
you have at least one measurable tumor lesion visible on a recent CT or MRI scan
you have a stored tumor tissue sample available from a previous biopsy or surgery
you are in good enough health to participate (your doctor will assess this using a standard health score)

You likely don't qualify if…

you have significant kidney problems (measured by a glomerular filtration rate below 60)
you have had major surgery or a serious invasive procedure within the past 4 weeks
you have an active, uncontrolled infection such as a bacterial, viral, or fungal infection
you have had radiation therapy within the past 2 weeks
you have low blood counts (very low neutrophils, hemoglobin, or platelets) that would make the study unsafe

What participation looks like

If you join this study, you will receive one or two radioactive imaging scans (called PET scans) on separate occasions. Each scan involves receiving an injection of the radioactive medication, waiting a short time for it to spread through your body, and then lying still in a scanner for imaging. The study is divided into two parts: in the first part, participants receive one type of scan; in the second part, participants may receive both the new medication and a comparison medication to help researchers understand which works better. The entire process takes a few hours per visit.

AI-generated summary from trial data · Jun 28, 2026 · Not medical advice

Trial locations(1 site)

Japan

Novartis Investigative Site, Chuo Ku, Tokyo